[Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain
This study shows that starting sacubitril/valsartan from hospital admission for heart failure is cost-effective from the perspective of the National Health Service in Spain.
Authors
- Héctor Barreiro Ramos (ORCID: https://orcid.org/0009-0000-1125-109X)
- Antonio García Quintana (ORCID: https://orcid.org/0000-0002-2475-2616)
- Javier Parrondo (ORCID: https://orcid.org/0000-0002-3258-5184)
Institutions
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Novartis (Spain) (ES)
Publication Details
- Journal
- Farmacia Hospitalaria
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.farma.2025.08.004
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Farmacéutica